Clinical trials: Metastatic Lung Cancer
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that…
- Conditions
- Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
- Trial name
- NCT05014815
- Testing
- Ociperlimab, Tislelizumab, Carboplatin
- Where
- 64 sites in United States, Australia and 6 more
- Volunteers
- 272 people
- Sponsor
- BeiGene
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
This study aims to evaluate the antitumor activity and safety of JDQ443 single-agent as first-line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor a KRAS G12C…
- Trial name
- KontRASt-06 (NCT05445843)
- Testing
- JDQ443
- Where
- 45 sites in United States, Argentina and 17 more
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study.
- Trial name
- NCT04585815
- Testing
- Sasanlimab Prefilled syringe, Encorafenib, Binimetinib
- Where
- 55 sites in United States, Australia and 2 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based chemotherapy compared with pembrolizumab plus platinum-based chemotherapy in…
- Trial name
- NCT05775289
- Testing
- Tobemstomig, Pembrolizumab, Paclitaxel
- Where
- 50 sites in United States, Australia and 9 more
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
Liver Neoplasms, Neoplasm Metastasis
Study of NS-9 in Patients With Liver Metastases
This study is to investigate the safety of NS-9 and to see how well it is tolerated in patients with cancer that has metastasized (spread) to the liver from another primary tumor.
- Conditions
- Liver Neoplasms, Neoplasm Metastasis, Local Neoplasm Recurrences
- Trial name
- NCT00094003
- Testing
- NS-9 [Poly I: Poly C]
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- NS Pharma, Inc.
Locally Advanced or Metastatic NSCLC
A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer
This is an open-label phase I/II preliminary study, including dose escalation, dose expansion, and efficacy expansion, to evaluate drug safety, tolerability, PK, and efficacy.
- Trial name
- NCT05662670
- Testing
- WJ13404 tablets
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Suzhou Junjing BioSciences Co., Ltd.
Non-Small Cell Lung Cancer
Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
This is a Phase 1/2, multi-center, open-label, dose-escalation trial of Ad-MAGEA3 and MG1-MAGEA3 in combination with pembrolizumab in patients with Non-Small Cell Lung Cancer who have completed a first standard therapy with at…
- Trial name
- NCT02879760
- Testing
- Ad-MAGEA3, MG1-MAGEA3, Pembrolizumab
- Where
- 6 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Turnstone Biologics, Corp.
Lung Cancer, Non-Small Cell
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
NSCLC comprises of approximately 84 percent (%) of all lung cancers and is often diagnosed at advanced stage due to poor prognosis.
- Trial name
- NCT04581824
- Testing
- Dostarlimab, Pembrolizumab, Chemotherapy
- Where
- 58 sites in United States, Argentina and 10 more
- Volunteers
- 243 people
- Sponsor
- GlaxoSmithKline
Lung Cancer
Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00061854
- Testing
- soblidotin
- Where
- 3 sites in United States
- Sponsor
- Daiichi Sankyo
NSCLC, Non Small Cell Lung Cancer
Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer
The goal of this clinical study is to learn more about the study drug TUB-040, safety, tolerability, pharmacokinetics (PK), and effectiveness in treating patients with unresectable or metastatic non-small cell lung cancer…
- Trial name
- NCT07806773
- Testing
- TUB-040
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Gilead Sciences
Non-Small Cell Lung Cancer With EGFR Mutation, Brain Metastases
Keynatinib in Treated Patients With NSCLC and Brain Metastases
The purpose of this study is to evaluate the safety and efficacy of Keynatinib capsules in patients with advanced non-small cell lung cancer (NSCLC) with brain metastasis or progression of brain metastasis after treatment with…
- Trial name
- NCT04824079
- Testing
- Keynatinib
- Where
- 5 sites in China
- Volunteers
- 16 people
- Sponsor
- Medolution Ltd.
Non-small Cell Lung Cancer, NSCLC
A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This is a single-arm, open-label, and multicenter phase Ⅱ study designed to evaluate the efficacy and safety of rulonilimab combined with chemotherapy in patients with advanced or metastatic non-small cell lung Cancer (NSCLC).
- Conditions
- Non-small Cell Lung Cancer, NSCLC, PD-1
- Trial name
- NCT05741021
- Testing
- F520, Pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Advanced Solid Tumors, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.
- Conditions
- Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC
- Trial name
- NCT04272034
- Testing
- INCB099318
- Where
- 24 sites in United States, Belgium and 5 more
- Volunteers
- 105 people
- Sponsor
- Incyte Corporation
Lung Lesion(s) Requiring Evaluation, Pulmonary Metastasis
Percutaneous Localization: Open-label Registry of Thoracic Surgery
The objectives of this study are to evaluate intraoperative percutaneous lung lesion marking assisted by electromagnetic guided percutaneous navigation and related tools.
- Conditions
- Lung Lesion(s) Requiring Evaluation, Pulmonary Metastasis, Pulmonary Nodule, Solitary, Peripheral Lung Lesions
- Trial name
- PLOTS (NCT04066699)
- Testing
- Percutaneous localization of suspicious lung lesion(s) using electromagnetic navigation and tools.
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Veran Medical Technologies
Non-small Cell Lung Cancer
A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This phase Ib/II study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of injectable BL-M07D1 in patients with HER2-mutated, locally advanced or metastatic non-small cell lung cancer.
- Trial name
- NCT06114511
- Testing
- BL-M07D1
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Solid Tumor Cancer, Non Small Cell Lung Cancer
A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in…
- Trial name
- NCT06848699
- Testing
- HLX43 dose 1, HLX43 dose 2, HLX43 dose 3
- Where
- 3 sites in China
- Volunteers
- 105 people
- Sponsor
- Shanghai Henlius Biotech
Non-Small Cell Lung Cancer With EGFR Mutation
A Phase I Study of CFT8919 in Patients With Advanced NSCLC
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of CFT8919 capsules in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying…
- Trial name
- NCT06641609
- Testing
- Dose-Escalation (Phase Ia) CFT8919 capsule, Dose-Expansion (Phase Ib) CFT8919 capsule, Cohort-Expansion (Phase Ic) CFT8919 capsule
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer Stage IV
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
The goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non-small cell lung cancer (NSCLC) patients.
- Trial name
- NCT06348199
- Testing
- SB27, Keytruda
- Where
- 93 sites in Bosnia and Herzegovina, Brazil and 12 more
- Volunteers
- 555 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Non Small Cell Lung Cancer
An External Control Arm Study in Non-Small Cell Lung Cancer
A study to create control arms using current and future information in patients with lung cancer.
- Trial name
- NCT07174388
- Where
- 11 sites in United States
- Volunteers
- 650 people
- Sponsor
- N-Power Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.